ProCE Banner Activity

KEYNOTE-028: Pembrolizumab in PD-L1+ Advanced Cervical Cancer

Slideset Download
Conference Coverage
Phase Ib trial of pembrolizumab in PD-L1–positive advanced cervical cancer showed promising 6-month OS of 67% and safety profile similar to that seen in other tumor types.

Released: June 09, 2016

Expiration: June 08, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals